Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

258
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
258
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

261
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
261
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

296
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
296
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

329
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
329
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

257
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Organocatalytic Synthesis of (Hetero)arylidene Malononitriles Using a More Sustainable, Greener, and Scalable Strategy.

Current organic synthesis·2024
Same author

Poly(<i>N</i>-vinylimidazole): A biocompatible and biodegradable functional polymer, metal-free, and highly recyclable heterogeneous catalyst for the mechanochemical synthesis of oximes.

Turkish journal of chemistry·2023
Same author

An overview of metal-free sustainable nitrogen-based catalytic knoevenagel condensation reaction.

Organic & biomolecular chemistry·2022
Same author

4,4'-trimethylenedipiperidine as a nitrogen heterocycle solvent and/or catalyst: Liquid phase tandem Knoevenagel-Michael condensation.

Turkish journal of chemistry·2021
Same author

Arene diazonium saccharin intermediates: a greener and cost-effective alternative method for the preparation of aryl iodide.

Turkish journal of chemistry·2021
Same author

New protocols for the synthesis of 5-amino-7-(4-phenyl)-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate esters using an efficient additive.

Turkish journal of chemistry·2021

Related Experiment Video

Updated: Sep 11, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.7K

A Structure-activity Relationship (SAR) Insight for the Most Effective Oral Antidiabetic Compounds-A Current Review.

Fathiy Mutalabisin1, Nader Ghaffari Khaligh1

  • 1Nanotechnology and Catalysis Research Center, Institute for Advanced Studies (IAS), Universiti Malaya, 50603 Kuala Lumpur, Malaysia.

Current Topics in Medicinal Chemistry
|August 15, 2025
PubMed
Summary

New oral anti-diabetic drugs (OADs) are crucial due to rising diabetes rates and limitations of current therapies. This review details OAD development, focusing on structure-activity relationships and emerging metal complex treatments for better diabetes management.

Keywords:
HeterocycleMetal complex derivatives.Oral anti-diabetic drug (OAD)Structure-activity relationshipType II diabetes mellitus

More Related Videos

Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.4K
Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.3K

Related Experiment Videos

Last Updated: Sep 11, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.7K
Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.4K
Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.3K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Endocrinology

Background:

  • Diabetes mellitus is a growing global health crisis with increasing prevalence and healthcare costs.
  • Existing oral anti-diabetic drugs (OADs) have limitations, including side effects and suboptimal long-term effectiveness.
  • There is an urgent need for novel anti-diabetic medications to improve patient outcomes.

Purpose of the Study:

  • To review the development of oral anti-diabetic drugs (OADs).
  • To explore the structure-activity relationship (SAR) in OAD design.
  • To highlight emerging anti-diabetic therapies, including metal complexes.

Main Methods:

  • Review of established and emerging classes of oral anti-diabetic drugs.
  • Analysis of structure-activity relationships (SAR) in drug development.
  • Discussion of synthetic chemistry's role in creating new anti-diabetic agents.

Main Results:

  • Examination of six major OAD classes: biguanides, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, and SGLT2 inhibitors.
  • Identification of structure-activity relationships guiding the design of effective OADs.
  • Introduction of metal complexes as a promising new class of OADs.

Conclusions:

  • Synthetic chemistry is vital for advancing diabetes treatment through novel OAD development.
  • Understanding SAR is key to optimizing existing and creating new anti-diabetic medications.
  • Emerging therapies like metal complexes offer potential for improved diabetes management and patient outcomes.